AbbVie Inc. diskutieren
AbbVie Inc.
WKN: A1J84E / Symbol: ABBV / Name: AbbVie / Aktie / Pharmazeutika / Large Cap /
222,60 €
-1,72 %
AbbVie (NYSE:ABBV) had its price target raised by analysts at Morgan Stanley from $269.00 to $270.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (NYSE:ABBV) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $275.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "outperform" rating reaffirmed by BMO Capital Markets.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "outperform" rating reaffirmed by William Blair.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its price target lowered by Cantor Fitzgerald from $250.00 to $240.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its price target raised by Guggenheim from $242.00 to $249.00. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "overweight" rating reaffirmed by Cantor Fitzgerald. They now have a $240.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its price target raised by Morgan Stanley from $270.00 to $278.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) was given a new $273.00 price target by Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $298.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its price target raised by Cantor Fitzgerald from $240.00 to $265.00. They now have an "overweight" rating on the stock.
Ratings data for ABBV provided by MarketBeat
AbbVie (ABBV) had its "buy" rating reaffirmed by HSBC Holdings plc.
Ratings data for ABBV provided by MarketBeat
Neueste Beiträge
Scotiabank in Microsoft Corp. diskutieren